RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase not stated

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking Union Medical College Hospital北京协和医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05860400, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Active acute or chronic infection (human immunodeficiency virus [HIV], tuberculosis, et al).

    Exclusion criterion 3

    Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).

    Exclusion criterion 4

  3. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05860400, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fulfilling all the following criteria before initiation of comprehensive treatment:

1.1 18 years of age or older, male or female.

1.2 Negative result of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).

1.3 Prior history of coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]).

1.4 Receiving standard treatment for secondary prevention of atherosclerotic coronary artery disease (AS-CAD) after the last coronary revascularization.

1.5 Hospitalization due to rapidly-progressive myocardial ischemia:

  • Typical symptoms of angina (Canadian Cardiovascular Society [CCS] III-IV) and non-invasive evidence of myocardial ischemia; and
  • Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.

1.6 Angiographic evidence of new coronary lesions (de novo stenoses or restenoses):

  • Occurred after the last coronary revascularization; and
  • Related to myocardial ischemia (location, extent, severity, et al).

1.7 Evidence of inflammation:

  • At least one of the markers indicating active inflammation has ever been elevated (erythrocyte sedimentation rate [ESR], high-sensitivity C-reactive protein [hs-CRP], interleukin [IL]-6, tumor necrosis factor [TNF]-α, ferritin, et al); or
  • Established diagnosis of systemic autoimmune disease or systemic vasculitis; or
  • Receiving immunosuppressive therapy.
  • Receiving comprehensive treatment, including ischemia-driven PCI which was performed no earlier than 40 days of the initiation of immunosuppressive therapy.

Exclusion Criteria:

  • Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).
  • Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
  • Active acute or chronic infection (human immunodeficiency virus [HIV], tuberculosis, et al).
  • Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).
  • Vital organ failure.
  • Life expectancy < 1 year.
  • Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.
  • In pregnancy or breast-feeding, or with intention to be pregnant during the study period.
  • Risk of non-compliance (history of drug addiction or alcohol abuse, et al).
  • Previous enrollment in this study.
  • Participation in another study within 30 days.
  • Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).
  • Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.

Quoted from ClinicalTrials.gov, NCT05860400, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05860400, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05860400